All In Biotech

Free tool

FAERS Monitor: Cysto-Conray Ii

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 017057 or its brand name (Cysto-Conray Ii, Iothalamate Meglumine). Reports on generic versions are filed under their own applications.

Reports

16

Serious

5

31% of reports

Hospitalization

2

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • incorrect route of drug administration8
  • wrong drug administered4
  • anaphylactoid reaction2
  • no adverse event2
  • agranulocytosis1
  • anaphylactic reaction1
  • angioedema1
  • cough1
  • drug ineffective1
  • expired product administered1
  • fixed eruption1
  • hypersensitivity1
  • pyrexia1
  • vomiting1

Reports by year received

View as table
YearReports
20091
20112
20121
20134
20142
20151
20162
20181
20251
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,143 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
fixed eruption1764.6114.5190
anaphylactoid reaction2639.2174.8716
wrong drug administeredSignal4590.3252.61,801
incorrect route of drug administrationSignal8294.3180.32,057
agranulocytosis170.710.617
expired product administered139.55.99
angioedema129.74.56
anaphylactic reaction123.83.65
no adverse event214.54.014
hypersensitivity17.11.11
cough14.70.70
pyrexia13.80.60
vomiting12.80.40
drug ineffective11.00.10

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.